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Background: Outcome measures for atopic dermatitis (AD) patients with pigmented skin have neither been
developed nor validated.
Objective: To compare the reliability and validity of four common AD outcomemeasures in patients with various
levels of skin darkness.
Method: The inter- and intra-rater reliability and construct validity of the EASI (EczemaArea and Severity Index),
objective-SCORing Atopic Dermatitis (oSCORAD), Three Items Severity index (TIS) and Six Areas, Six Sites Atopic
Dermatitis (SASSAD) were evaluated in 18 patients of various levels of skin darkness, using their full body
photographs, by ﬁve trained clinicians.
Results: The inter-rater reliability intraclass coefﬁcient (ICCs) and 95% conﬁdence intervals were poor for
highly pigmented patients: EASI -.054(-.200 to .657), oSCORAD -.089(-.206 to .598), TIS -.21(-.24 to .147),
SASSAD -.071(-.200 to .631); fair for mildly pigmented patients: EASI .464(.140-.839), oSCORAD
.588(.265-.89), TIS.524(.200-.865), SASSAD .41(.045-.775); and fair to good for non-pigmented patients:
EASI .64(.330-.908), oSCORAD .586(.263-.889), TIS .403(.09-.809), SASSAD .667(.358-.916). Erythema
likely contributed to the inter-rater variability. Construct validity had signiﬁcant correlations across
all measures in non-pigmented patients, but no correlations in highly pigmented patients.
Conclusion: AD outcome measures have poor reliability and validity in highly pigmented patients, with
variations in erythema perception being a contributor.
© 2015 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Skin color contains vital diagnostic clues in dermatology, as it re-
ﬂects the underlying pathological process. Patients with pigmented
skin are a complex population in dermatology. Inﬂammatory conditions
such as atopic dermatitis (AD) and psoriasis are more difﬁcult to assess
in these patients, putting them at risk for misdiagnosis or mistreatment.
Many times, patientswith skin of color have been excluded from clinical
trials in dermatology due to the difﬁculties of assessing disease severity.
There are many reasons to account for the difﬁculties in assessing
pigmented patients with AD. Phenotypic variations secondary to genet-
ic differences is one reason; for example, ﬁlaggrin-2mutation variationsependent learning project (ILP)
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.in AD have been found in African-American patients, and have been as-
sociated with a more persistent disease course (Margolis et al., 2014;
Torrelo, 2014). Another example is that pigmented skin has been
shown to be less likely to develop erythema when exposed to irritants
(Berardesca and Maibach, 2003). Also, cultural and environmental fac-
tors can change how the skin is cared for, leading to further heterogene-
ity in manifestation. In addition, the clinician’s perception of color may
be distorted by the background skin pigmentation or be mistaken for
post-inﬂammatory hyperpigmentation (Ahmad Fadzil et al., 2009).
Furthermore, clinical experience with managing patients with skin of
color is a contributing factor. As a result, considerable intrarater
and interrater variations in assessing the patient can occur, while the
validity is compromised by the clinical heterogeneity.
AD is a common dermatological condition that can affect patients
of all ethnicities and skin types. In the pediatric population, AD has
comparably high prevalence of 17% in the United States, 14% in England,
24% in Japan, 17% in Korea, 17% in South Africa (mixed Caucasians and
Blacks), 20% in Kenya, and 32% in Melbourne, Australia (Esamai et al.,matologic Society. This is an open access article under the CC BY-NC-ND license
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et al., 2009; Sugiura et al., 1998; Zar et al., 2007). A systematic review
in 2012 has also found that in Africa, Eastern Asia, Western Europe
and parts of Northern Europe, trends in AD were mainly increasing
(Deckers et al., 2012).
The course of AD is typically chronic, requiring ongoing monitoring
and an accurate assessment instrument. Also, many clinical trials have
being conducted to evaluate interventions for AD, calling for a uniform
outcome measure. Signiﬁcant international efforts have been made to
facilitate the standardization and validation of AD outcome measures.
TheHarmonisingCoreOutcomeMeasures (HOME) for eczema initiative
has had several meetings (Chalmers et al., 2014; Schmitt andWilliams,
2010; Schmitt et al., 2012), and conﬁrmed that excoriation, erythema,
edema, or papulation and licheniﬁcation are four essential components
for the assessment of AD severity. A recent systematic review indicated
that out of the 16 proposed outcome measures used in clinical trials,
only the EASI (EczemaArea and Severity Index) and the SCORing Atopic
Dermatitis (SCORAD) have received adequate validation (Schmitt et al.,
2013). Meanwhile, a recent HOME consensus recommended the EASI
alone as the optimal outcome measure (Chalmers et al., 2014).
Despite all of the above progress, the assessment of AD in
pigmented-skin patients is still a grey area requiring attention. In fact,
a studyhas found the underreporting of patient’s skin type in clinical tri-
als, with only 59.5% of the clinical trials published in the United States
between 2000 and 2009 reporting the patient’s race or ethnicity
(Hirano et al., 2012). Another systematic review showed that there is
a dearth of studies demonstrating efﬁcacy of systemic AD therapy in
different racial and ethnic patient subsets in the United States
(Bhattacharya and Silverberg, 2014).
The aim of this studywas to contribute to the expandingwork in the
standardization of AD outcomemeasures by addressing the issue of dis-
ease assessment in patients with pigmented skin. A prospective study
was conducted to compare the interrater and intrarater reliability, as
well as convergent construct validity, of the four most commonly used
atopic dermatitis outcome measures in patients with various levels of
skin darkness. This study also aimed to explore the underlying factors
contributing to the variations, such as erythema.
Materials and methods
This prospective study was granted ethical approval from the South
Eastern Sydney Health District Human Research Ethics Committee
Northern Sector (reference: HREC/12/POWH/155).
Outcome measures tested
The outcomemeasures evaluated in this study were chosen as these
have beenmost frequently validated as per a systemic review published
in 2013 (Schmitt et al., 2013). These include the EASI, SCORAD, of which
has a clinician-reported only version called the objective SCORAD
(oSCORAD), Three Items Severity index (TIS) and Six Areas, Six Sites
Atopic Dermatitis (SASSAD; Berth-Jones, 1996; Haniﬁn et al., 2001;
Stalder and Taieb, 1993; Wolkerstorfer et al., 1999).
Participants and assessors
The full-body photographs of 20 patients with AD were obtained
from dermatology outpatient clinics from Sydney. Two patients were
later excluded as they had more than two body parts missing from
their full-body photographs.
Five assessors participated in the scoring process (D.F.M, M.J.D,
A.G.H, S.V.J, and K.L). All assessors were either qualiﬁed dermatologists
or have been doing full-time dermatology research, and hence had
been familiar with atopic dermatitis. Two (M.J.D and K.L) had trained
in the Philippines and were used to darker-skinned patients. One had
trained in North Carolina (D.F.M), where approximately one third ofpatients were African-American. All assessors were required to attend
a training lecture on the use of the EASI, oSCORAD, TIS, and SASSAD.
Also, the assessors were required to attend a debrieﬁng session prior
to each scoring session to raise queries regarding the administration of
these scoring systems. The assessors were completely blinded to the
identity of the patients chosen.
Scoring process
The assessments were performed for 2-hour sessions, over 4 days.
Each session was limited to 2 hours in length, to avoid assessor fatigue.
Full-body photographs of the 18 patients were presented on a
screen of at least 1.5 m by 1.5 m. Three patients with various levels of
skin pigmentations, whose identities were unknown to the assessors,
were also arranged by a separate investigator to have their photographs
repeatedly shown at the end of the 18 patients for intrarater reliability
testing. For each of the patients scored, the assessors were given four
color-coded scoring sheets including the four measures. The assessors
were given the time to view the photographs until they were satisﬁed
with their scores. Each assessor was neither allowed to look at their
own scores from the other outcome measures, nor another assessor’s
scores.When any patients hadminor body partsmissing, whichﬁve pa-
tients did, all assessors were asked not to assess the particular missing
body part across all scores.
Data input
All outcome measure scores were calculated by two separate study
investigators. Data input was performed by one investigator, then
separately double-checked by another investigator. The ﬁve patients
with minor body parts missing from their photographs had their EASI,
SASSAD, and oSCORAD’s total denominators reduced to reﬂect the
exclusion of the corresponding body parts.
Categorization of skin pigmentation levels
Each patient’s skin pigmentationwas scored by all assessors on a nu-
merical scale of 0 to 10, ranging from0 representing nopigmentation, to
10 representing the darkest level of pigmentation. The average of each
patient’s pigmentation score across the ﬁve assessors was then used
to categorize patients into three groups: nonpigmented (score range
0-3), mildly pigmented (score range 3.1-7) and highly pigmented
(score range 7.1-10). These ranges were chosen as they divide into
three approximately equal categories.
Statistical analysis
All statistical analyses were performed using SPSS Version 22.0
(Armonk, NY; IBM Corp.). A professor of statistics (M.G.L) from the
Kirby Institute of University of New South Wales provided help with
choosing the most appropriate statistical tests.
For reliability testing, both interrater and intrarater reliabilities were
assessed by the Intraclass coefﬁcient (ICC)with 95% conﬁdence interval
(CI), using a one-way random analysis variance model. When an ICC is
below .40, the clinical correlation is poor; when it is between .40 and
.59, the level of correlation is fair; when it is between .60 and .74, the
level of correlation is good; and when it is between .75 and 1, the
level of clinical signiﬁcance is excellent (Cicchetti, 1994). Scatterplots
were constructed to illustrate interrater differences across all outcome
measures and skin types.
To determinewhether the erythema components contributed to the
variability in reliability, the erythema component and the “total minus
erythema component” of each outcomemeasurewere separately input-
ted. The ICCs and coefﬁcient of variations (CV) means of the erythema
component and the “total minus erythema component”were then cal-
culated. The null hypothesis is that the ICC for the erythema component
Table 2
Characteristics of the Patients for Intra-rater Reliability Testing (n = 3).
Patient 1 Patient 2 Patient 3
Age⁎ 60 22 25
Sex Female Female Female
Ethnicity Caucasian Asian African
Average pigmentation score 2.0 5.4 7.6
⁎ When the investigatorwas unable to ascertainwhat the patient’s agewaswhenhis/her
photo was taken, an estimate of age was made by two separate investigators.
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while the CVmeans across all patients should be smaller. This would in-
dicate that erythema did not contribute to the variability of the scores.
To determine the signiﬁcance of the difference in the ICCs, the CVs of
the erythema components and the “total minus erythema components”
were correlated using the paired T-test.
For convergent construct validity, all outcome measures were
correlatedwith each other, and the respective Spearman rho correlation
coefﬁcients were determined.
Additional assessments by an overseas dermatologist
Additional convergent construct validity testing was performed by a
South African dermatologist with expertise in assessing atopic dermatitis
in pigmented skin patients (N.C.D). The results were compared to the
Australian dermatologists’ results to determine whether experience
would improve the validity of outcome measures in highly pigmented-
skin patients.
Results
Demographics
Altogether, 18 patients were included in the ﬁnal analysis for
interrater reliability and convergent construct validity (Table 1).
Of these, three were of Asian background, 11 were of Caucasian
background, two were of African background, and four were of Indian
background. Three patients were also used for intrarater reliability
analysis (Table 2).
Inter-rater reliability
The interrater reliability ICCs (and their 95% CIs) for the highly
pigmented patients were: TIS, -.21 (-.24 to .147); SASSAD, -.071 (-.2 to
.631); EASI, -.054 (CI: -.2 to .657); and oSCORAD, -.089 (-.206 to .598),
indicating very poor interrater reliabilities. The ICCs for the mildly
pigmented patients were: TIS, .524 (.2-.865); SASSAD, .341 (.045-
.775); EASI, .464 (.14-.839); and oSCORAD, .588 (.265-.890), indicating
fair interrater reliability. The ICCs for the nonpigmented patients
were: TIS, .403 (.09-.809); SASSAD, .667 (.358-.916); EASI, .64 (.33-
.908); and oSCORAD, .586 (.263-.889), indicating fair interrater reliabi-
lity for the TIS and oSCORAD, and good interrater reliability for the
EASI and SASSAD.
Interrater scatterplots showed that, in highly pigmented skin
patients, all scores have poor interrater reliability regardless of disease
severity. In mildly pigmented patients, all scores had poorer interrater
reliability with increased disease severity. In nonpigmented patients,
interrater reliability does not appear to be inﬂuenced bydisease severity
(Supplementary Fig. 1 and Table 3).
Erythema’s contribution to variability
The inter-rater reliability ICCs and coefﬁcient of variations (CV)
means of the erythema components and “total minus erythemaTable 1
Characteristics of the Total Patient Cohort (n = 18).
Highly pigmented⁎ Mildl
N (%) 4 (22.2) 7 (38
Age range (years) 7-40 2-65
Mean age (years) 26.8 29.1
Male (%) 2 (50) 5 (71
Female (%) 2 (50) 2 (28
⁎ The pigmentation groupswere derived from themeanpigmentation given by the assessors: n
(score range 7.1-10).components” were compared against each another. For the highly
pigmented patients, the EASI and oSCORAD had slight, but clinically sig-
niﬁcant, superior reliabilities when the erythema components were ex-
cluded (EASI: -.171 vs. -.072, p = .034; oSCORAD: -.230 vs. -.062, p =
.04; Table 3). This superior reliability was not present in the TIS or
SASSAD, or in any other pigmentation groups. These results suggest
that the erythema components have likely contributed to the variability
of EASI and oSCORAD inhighly pigmented skin patients. However, given
the poor ICCs of the “total minus erythema components,” other factors
were likely to have also contributed to the variability.
When comparing the CVmeans (an indicator of variability) in highly
pigmented patients, there were higher CV means in the erythema
components than the “total minus erythema components”, across all
outcomemeasures (Table 4). The higher CVmean of the erythema com-
ponentwas not present in any other outcomemeasure or pigmentation
groups, except for SASSAD in mildly pigmented patients. These results
were also evident of erythema’s contribution to the variability of the
outcome measures in highly pigmented patients.
Intrarater reliability
For the patients with highly pigmented skin, the intrarater reliability
ICCs were poor in all scores except for the SASSAD (Table 5). For the
patients with mildly pigmented skin, the intrarater reliability ICCs
were poor in the EASI and oSCORAD, and fair for TIS and SASSAD. For
the patients with nonpigmented skin, the intra-rater reliabilities of the
oSCORAD and TIS were poor, but for EASI and SASSAD were good.
Given the wide 95% CIs of the results, the ﬁndings were limited
by poor power. However, these results may suggest that in patients
with highly pigmented skin, intrarater unreliability is more likely to
be unreliable.
Convergent construct validity
In highly pigmented patients, none of the scoring instruments signif-
icantly correlated with each other. In mildly pigmented patients,
SASSAD is not statistically signiﬁcantly correlated with any of the
other scoring instruments. The correlations of the other three outcome
instruments were EASI with TIS: .829 (p= .021), EASI with oSCORAD:
.857 (p = .014), and oSCORAD with TIS: .919 (p = .003). In
nonpigmented patients, the correlations of all four outcome measures
were mostly statistically signiﬁcant: EASI with TIS: .919 (p = .003),
EASI with oSCORAD: 1.000 (p b .01), EASI with SASSAD: .786 (p =
.036), oSCORAD with TIS: .919 (p = .003), oSCORAD with SASSAD:
.786 (p = .036), and TIS with SASSAD: .793 (p = .033). These resultsy pigmented Nonpigmented Overall
.9) 7 (38.9) 18 (100)
1-65 1-65
32.3 29.8
.4) 3 (42.9) 10 (55.6)
.6) 4 (57.1) 8 (44.4)
onpigmented (score range 0-3),mildly pigmented (score range 3.1-7), andhighly pigmented
Table 3
Inter-rater Reliability ICCs of the EASI, OSCORAD, TIS, and SASSAD Total scores; the Erythema Component; and the “Total Minus Erythema Component” by Pigmentation Level.
EASI oSCORAD TIS SASSAD
Highly pigmented group ICCs (95% CI; n = 4)
Total score .509 (.300-.731) -.089 (-.206 to .598) -.210 (-.240 to .147) -.071 (-.201 to .631)
Erythema -.171 (-.200 to .363) -.230 (-.245 to .015) -.055 (-.200 to .656) -.088 (-.206 to .599)
Total minus erythema -.072 (-.201 to .628) -.062 (-.198 to .645) -.229 (-.308 to .399) -.144 (-.222 to .462)
Mildly pigmented group ICCs (95% CI; n = 7)
Total score .464 (.140-.839) .588 (.265-.890) .524 (.199-.865) .341 (.045-.775)
Erythema .607 (.290-.896) .636 (.320-.906) .603 (.281-.895) .601 (.280-.895)
Total minus erythema .358 (.570-.785) .500 (.176-.855) .413 (.100-.814) .193 (-.051 to .670)
Nonpigmented group ICCs (95% CI; n = 7)
Total score .640 (.330-.908) .586 (.263-.889) .403 (.092-.809) .667 (.358-.916)
Erythema .749 (.470-.941) .423 (.108-.820) .409 (.097-.812) .783 (.526-.950)
Total minus erythema .533 (.209-.869) .560 (.235-.879) .303 (.180-.751) .459 (.139-.837)
Overall ICCs (95% CI; n = 18)
Total score .431 (.223-.673) .621 (.423-.805) .480 (.270-.710) .504 (.294-.747)
Erythema .609 (.409-.798) .509 (.300-.731) .568 (.363-.772) .701 (.522-.853)
Total minus erythema .509 (.300-.731) .597 (.396-.790) .436 (.228-.677) .340 (.141-.598)
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measures in highly pigmented patients.
Additional assessments by an overseas dermatologist
The same 18 patients were assessed by the South African
dermatologist (N.C.D). In highly pigmented patients, none of the
scoring instruments signiﬁcantly correlated, except for EASI with
SASSAD (p = .051). In mildly pigmented patients, all outcome
measures correlated well, but were limited by low power, as
there were only two patients in this group (as per pigmentation
score out of 10 rated by the South African dermatologist). In
nonpigmented patients, the correlations of all four outcome
measures were mostly statistically signiﬁcant: EASI with TIS: .645
(p = .023), EASI with oSCORAD: .867 (p b .01), EASI with SASSAD:
.967 (p b .01), oSCORAD with TIS: 1.000 (p b .01), oSCORAD with
SASSAD: .872 (p b .01), and TIS with SASSAD: .648 (p= .023). These re-
sults were comparable to the Australian dermatologists, conﬁrming the
poorer convergent construct validity of all outcomemeasures in highly
pigmented patients.
Discussion
To the authors’ knowledge, this is the ﬁrst study to evaluate the
commonest AD outcome measures in patients with pigmented skin.
Overall, all AD outcome measures—the EASI, the oSCORAD, the TIS,
and the SASSAD—may have poor reliability and validity in patients
with very dark skin. All four measures had very poor interrater reliabil-
ity when used in patients of highly pigmented skin with ICCs of b .4,
regardless of disease severity. Thus, we would warn against theTable 4
Coefﬁcient of Variation (CV)Means of the Erythema Components Versus the “TotalMinus
Erythema Components” of the Four Outcome Measures by Pigmentation Level.
EASI oSCORAD TIS SASSAD
Highly pigmented group CVs (n = 4)
Erythema .987 .961 1.01 .852
Total minus erythema .525 .331 .499 .427
Mildly pigmented group CVs (n = 7)
Erythema .359 .323 .249 .323
Total minus erythema .659 .283 .377 .471
Nonpigmented group CVs (n = 7)
Erythema .578 .284 .201 .387
Total minus erythema .746 .526 .807 .647performance of AD severity assessments by two different doctors, at dif-
ferent time points, in dark-skinned patients. All four measures also pro-
duced poorer results when used in mildly pigmented patients as
compared to nonpigmented patients, with the level of variation increas-
ing with disease severity. Also, all measures had poor intra-rater reli-
ability in highly pigmented patients, although the power of the results
was limited by the small sample size.
The study suggested that erythema is a contributor to the inter-rater
variations, with higher CVmeans of erythema components compared to
the “totalminus erythema components.” This ﬁnding echoed a previous
study byBen-Gashir andHay (2002),which investigated the effect of in-
cluding and excluding erythema assessment on the assessment of AD
severity; when the erythema component of the oSCORADwas excluded
and adjusted for the total, disease was found to be severer in Black
children. Our study went into more breadth to evaluate this issue.
Given that, in our study, the interrater ICCs of the “totalminus erythema
components” were also poor in the highly pigmented patients, other
factors are likely have also contributed to the variability.
The inferior reliability of all outcome measures in nonpigmented
patients suggested by this study when compared to other studies is
likely due to the fact that patients were virtually scored instead of in a
routine clinic setting. Three-dimensional assessments for licheniﬁcation
and papulation were likely compromised, as was the feeling of
heat via palpation to distinguish between active inﬂammation and
postinﬂammatory hyperpigmentation. Given the recent growth of
teledermatology worldwide, this study highlighted that virtual scoring
may be suboptimal for a thorough and accurate assessment of AD. The
authors also acknowledge the limited number of patients used for this
study, given the difﬁculties to obtain high-deﬁnition, full body photos
of very dark patients. This was compensated for by using at least ﬁve
trained clinicians to perform the assessments. Another limitation was
that being a single-center study, the poorer reliability and validity may
not be demonstrated in all other settings and locations. To compensate
for this, a South African dermatologist experienced with N95% of her
patients being Fitzpatrick skin types V-VI from Durban, South Africa,
was invited to also score the same patients for convergent construct
validity analyses.
Regarding construct validity, all four measures were again inferior in
highly pigmented patients, even when scored by a South African dermato-
logist with experience in assessing dark skin. This is suggestive of under-
lying heterogenicity of clinical signs in highly pigmented patients, which
may not have been included in the four common AD outcome measures.
From this study, a newoutcomemeasuremay be needed to take into
account the manifestation and perception of erythema, as well as other
clinical heterogeneity found in dark AD patients such as ichthyosis or
prurigo nodularis (Vachiramon et al., 2012). A grey scale may more
Table 5
Intra-rater Reliability ICCs of the EASI, oSCORAD, TIS and SASSAD by Pigmentation Level.
EASI oSCORAD TIS SASSAD
Highly pigmented .391 (-.528 to .911) .075 (-.728 to .832) -.434 (-.899 to .574) .787 (.064-.975)
Mildly pigmented .037 (-.746 to .819) -.537 (-.922 to .476) .429 (-.494 to .918) .458 (-.467 to .924)
Nonpigmented .830 (.184-.980) -.151 (-.818 to .747) -.760 (-.922 to .122) .699 (-.134 to .963)
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temperature scale may help to distinguish between inﬂammation and
post-inﬂammatory hyperpigmentation. The development of the new
outcome measure should be followed by a multicenter validation
study in a routine clinical setting. In the ﬁeld of dermatology, this
study also has implications for the validation of psoriasis outcome mea-
sures, aswell as patch test readingprotocols, inpatientswithverydark skin.
In conclusion, the study suggests that AD outcome measures have
poor reliability and validity in patients with very dark skin. A new out-
come measure may be needed to take into account the manifestation
and perception of erythema and other clinical signs in these patients.
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doi.org/10.1016/j.ijwd.2015.05.002.Acknowledgments
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